Back to search
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma trials you may qualify forThis study is an open-label, multi-cohort real-world research that explores the efficacy and safety of different second-line treatment regimens for gastric/gast…
This trial is a registrational Phase III, randomized, controlled, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in pati…
Gastric cancer is one of the most common and deadly cancers globally, characterized by a poor prognosis. Approximately 70% of patients are diagnosed at an advan…
The goal of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and anti-tumor activities of cadonilimab in combination w…
To evaluate the efficacy and safety of anlotinib combined with TQB2450 and the SOX regimen as first-line treatment for advanced gastric cancer with low PD-L1 ex…
Gastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a…